Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific (NYSE:MLSS) has signed an agreement with a prestigious Northeast teaching hospital for the purchase of its CompuFlo® Epidural and CathCheck™ Verification System disposables. This follows a successful trial demonstrating the technology's safety and efficacy, enhancing accuracy in epidural procedures. The CompuFlo system is expected to reduce healthcare costs associated with morbidity and significantly decrease monitoring time for catheter placements. The company aims to expand its reach beyond labor and delivery, targeting pain management and outpatient centers.
Milestone Scientific (NYSE:MLSS) announced that CEO Arjan Haverhals will present at the Benzinga All Access event on December 16, 2021, at 10:40 A.M. Eastern Time. The presentation will recap key activities from 2021 and outline the company's sales pipeline and goals for 2022. The event will be broadcast live, and an archived recording will be accessible on Milestone's investor relations website. Milestone Scientific is known for its computerized drug delivery instruments, enhancing patient comfort and safety with innovative technologies.
Milestone Scientific (NYSE:MLSS) announced a significant step in expanding its CompuFlo Epidural instrument into the pain management market. Dr. Miguel de la Garza has started using the instrument in his practice, following approval by Surgery Partners, enhancing safety in procedures with reduced risk of complications. The overall addressable market for epidural anesthesia is around $5 billion, with pain management being twice the size of labor and delivery. CEO Arjan Haverhals emphasized the potential for capturing a significant market share with this innovative technology.
Milestone Scientific reported a 69% revenue increase to $2.1 million for Q3 2021, compared to $1.2 million in Q3 2020. This growth is driven by the reopening of dental offices and progress in their Medical segment, notably their CompuFlo Epidural instrument's deployment in Florida's Memorial Healthcare network. Despite the revenue growth, the operating loss expanded to $(2.0 million), up from $(1.5 million) in the prior year. The company has a robust financial position with about $14.5 million in cash. Milestone anticipates expanding its global presence with new distributors and aims for further growth in the medical business.
Milestone Scientific (NYSE: MLSS) announced a conference call scheduled for November 15, 2021, at 11:00 A.M. ET. The call will address the company’s third-quarter financial results for the period ending September 30, 2021, alongside updates on corporate progress and developments. Investors can access the call via telephone or a webcast. Additionally, an audio replay will be available until November 29, 2021. Milestone Scientific specializes in computerized drug delivery systems aimed at improving injection precision and patient comfort.
On October 18, 2021, Milestone Scientific (NYSE:MLSS) announced that CEO Arjan Haverhals will present at the Dawson James Securities Small Cap Growth Conference on October 21, 2021. The presentation is scheduled for 1:10 PM Eastern Time, with additional one-on-one meetings for qualified investors planned throughout the event. Interested parties can access the live webcast and archived recordings through the company's investor relations section. Milestone Scientific specializes in computerized drug delivery systems aimed at improving patient comfort during injections.
Milestone Scientific Inc. (NYSE:MLSS) has expanded its international presence by signing new distribution agreements in Canada, Slovenia, and the UAE for its CompuFlo Epidural Instrument. The partnerships aim to enhance women's health by providing safer pain relief during childbirth. Additionally, increased usage of the device at a leading German hospital showcases rising interest and demand.
Milestone Scientific Inc. (NYSE: MLSS) announced its participation in the Fall Harvest - Best Ideas from the Buy-Side conference, running from October 5-8, 2021. CEO Arjan Haverhals will present on October 6, 2021, at 9:30 AM ET, with the presentation available for live streaming and replay. This virtual conference features 36 top investment ideas recommended by qualified institutional investors. Milestone Scientific specializes in computerized drug delivery instruments aimed at enhancing patient comfort and safety during injections.
Milestone Scientific (NYSE:MLSS) has announced that Memorial Regional Hospital in Florida has begun utilizing its CompuFlo Epidural Instrument. This approval allows Milestone to supply both the CompuFlo and CathCheck Verification System disposables across the Memorial Healthcare System network. This milestone follows significant due diligence and expands Milestone’s sales pipeline. Clinical data supports that these instruments enhance safety and efficiency in epidural procedures, potentially reducing complications and costs for healthcare providers.
Milestone Scientific (MLSS) reported a significant revenue increase of 1,329% for Q2 2021, totaling $2.4 million, driven by a recovery in the dental sector. Gross profit rose to $1.4 million, with a reduced operating loss of $(2.9) million compared to $(3.2) million in Q2 2020. The company noted a healthy balance sheet with approximately $16 million in cash. CEO Arjan Haverhals expressed optimism about growth prospects, driven by new sales initiatives and expanding the sales force and international distribution.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
